Pyoderma Gangrenosum
📧 Sign up to get email alerts when something new happens for Pyoderma Gangrenosum.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum [Phase 3]
A Phase 3 clinical trial to evaluate spesolimab in people with Pyoderma Gangrenosum is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Spesolimab in Pyoderma Gangrenosum [Phase 2]
A Phase 2 trial evaluating Spesolimab for Pyoderma Gangrenosum was terminated, and results have been posted.
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) [Phase 2]
A Phase 2 clinical trial is evaluating guselkumab in adults with Pyoderma gangrenosum and the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum [Phase 2]
Phase 2 clinical trial evaluating SHR-1139 injection in patients with pyoderma gangrenosum. The study status is NOT_YET_RECRUITING.
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum [Phase 2]
A Phase 2 clinical trial evaluating the efficacy and safety of SHR-1139 injection in adult patients with Pyoderma Gangrenosum; the study sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications [Phase 4]
This Phase 4 update reports outcomes from hyperbaric oxygen therapy across several emerging indications, with the study currently not yet re…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum [Phase 3]
A Phase III trial evaluating vilobelimab for ulcerative pyoderma gangrenosum has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: A Novel Therapeutic Treatment of Pyoderma Gangrenosum [Phase 4]
Phase 4 trial evaluating a novel treatment for Pyoderma gangrenosum has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-08-11Clinical Trial Update: Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum [NA]
A clinical trial evaluating autologous platelet-rich plasma therapy for Pyoderma Gangrenosum has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG)
A completed clinical trial evaluating adverse events and changes in disease state in adults with Pyoderma Gangrenosum treated with Humira (a…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum [Phase 2]
A Phase II open-label study of Xilonix in Pyoderma Gangrenosum has completed, according to Janssen's clinical trial update.
-
CLINICAL_TRIALS withdrawal · 2025-06-27Clinical Trial Update: Deucravacitinib in PG [EARLY_Phase 1]
The EARLY Phase 1 trial of deucravacitinib for pyoderma gangrenosum has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) [Phase 2]
A Phase 2 clinical trial assessing baricitinib for treating adults with Pyoderma gangrenosum has completed.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum [Phase 3]
A Phase 3 study evaluating hyperbaric oxygen therapy for Pyoderma gangrenosum has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum [Phase 2]
A Phase 2 exploratory trial of IFX-1 in patients with pyoderma gangrenosum has completed, with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum [Phase 1, Phase 2]
A single-arm clinical trial investigated the potential effect of secukinumab (anti-IL-17) in treating pyoderma gangrenosum; the study comple…
-
CLINICAL_TRIALS trial_result · 2022-06-06Clinical Trial Update: An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum [Phase 2]
Phase 2 open-label proof-of-concept study evaluating ixekizumab for pyoderma gangrenosum has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum [Phase 2]
Phase 2 trial of APD334 in pyoderma gangrenosum was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2021-03-09Clinical Trial Update: A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan [Phase 3]
Phase 3 trial evaluating adalimumab for active pyoderma gangrenosum in Japan has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-27Clinical Trial Update: Canakinumab for Pyoderma Gangrenosum [Phase 2]
A Phase 2 trial evaluating canakinumab for Pyoderma Gangrenosum has completed.
-
CLINICAL_TRIALS research · 2016-09-27Clinical Trial Update: Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Observational study by the University of Zurich investigating the genetic architecture of neutrophil-mediated inflammatory skin diseases, li…
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum [Phase 3]
A Phase 3 study evaluating Gevokizumab for active ulcers in Pyoderma gangrenosum was terminated.
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum [Phase 3]
Phase 3 trial evaluating gevokizumab for active ulcers in Pyoderma Gangrenosum has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-04-27Clinical Trial Update: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum [Phase 3]
A 2-year, open-label safety extension study of gevokizumab in patients with pyoderma gangrenosum has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-02-03Clinical Trial Update: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum [Phase 2]
A Phase 2 proof-of-concept study of gevokizumab for Pyoderma gangrenosum has completed, sponsored by XOMA (US) LLC.